Phage therapy

Inventors

Pouillot, Flavie • BLOIS, HELENE

Assignees

Phaxiam Therapeutics SA

Abstract

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

Core Innovation

The invention provides an antibacterial composition comprising at least two bacteriophages having lytic activity against a Pseudomonas aeruginosa strain and a pharmaceutically acceptable excipient or carrier. The bacteriophages are selected from bacteriophages whose genome comprises a nucleotide sequence of any one of SEQ ID NOs: 1 to 7 or a sequence having at least 99% identity thereto, and the excipient or carrier comprises a preservative in an amount effective to preserve the activity of the bacteriophages.

The invention further provides therapeutic and non-therapeutic uses of the bacteriophage-based compositions. A mammal in need thereof is treated by contacting the mammal infected with a P. aeruginosa strain with an antibacterial composition in an amount effective to treat the P. aeruginosa infection, where the composition comprises at least two bacteriophages having lytic activity against the P. aeruginosa strain. In particular embodiments, the infection being treated is an infection of the respiratory tract.

The invention also covers improving the condition of a mammal by modifying the microbial flora, wherein the microbial flora comprises the P. aeruginosa strain, and decontaminating a material by exposing the material to an amount of the antibacterial composition effective to decontaminate the material. The invention further includes preparing a composition by separately producing the at least two bacteriophages selected from those having genome nucleotide sequences of SEQ ID NOs: 1 to 7 or at least 99% identity, and combining the bacteriophages with a suitable carrier or excipient.

A separate therapeutic method exposes a mammal with a P. aeruginosa infection to an effective amount of a lytic bacteriophage, or to isolated nucleic acid, or to an isolated polypeptide encoded by a bacteriophage, with the nucleotide sequence selected from SEQ ID NOs: 2 to 7 or having at least 99% identity, including polypeptides encoded by nucleic acids with those sequence criteria.

Claims Coverage

The independent claims cover an antibacterial composition and multiple methods of use for treatment, microbial flora modification, decontamination of materials, preparation of the composition, and treatment using phage nucleic acids and polypeptides. Across the independent claims, the core inventive features are the selection of bacteriophages by genome nucleotide sequences of SEQ ID NOs: 1 to 7, or sequences having at least 99% identity thereto, and their use in the stated compositions and methods.

Overall, the independent claims establish coverage for an antibacterial composition containing at least two lytic bacteriophages selected by SEQ ID NO or at least 99% identity genome sequence criteria, including preservative-containing pharmaceutically acceptable excipients or carriers. They also cover methods of treating mammalian P. aeruginosa infections, including respiratory tract infections in a dependent claim, improving a mammal’s condition by modifying microbial flora, decontaminating a material, separately producing and combining the selected bacteriophages with a suitable carrier or excipient, and treating infection using lytic bacteriophages as well as isolated nucleic acids and isolated polypeptides encoded by such phages or nucleic acids.

Stated Advantages

Documented Applications